Build 
& support.

Octalfa is a family-owned holding company that has been creating and supporting innovative businesses since 2007.

Manifesto

Octalfa is a family-owned holding company that has been creating and supporting innovative businesses since 2007. We have funded 15 companies in life sciences and chemistry and have directly co-founded four groundbreaking ventures alongside visionary entrepreneurs.

Today, we operate through three complementary approaches: seed financing, business creation, and company acquisition.

Driven by innovation, hard work, and growth, we are patient partners who bring our expertise to new entrepreneurial projects.

Investment Thesis

Amorçage d'entreprise

Seed Financing

We invest in companies at the earliest financing stage, with the ability to follow up in subsequent rounds

Amorçage d'entreprise
Target sectors

Open

Investment range

€150k – €400k

Objective

10 investments in France

Création d'entreprise

Company Creation

We support entrepreneurs-in-residence in developing their ventures. We then co-found and fund the company

Création d'entreprise
Target sectors

Open

Investment range

€100k – €2M, depending on maturity and needs

Reprise d'entreprise

Business Acquisition & Succession

We finance company buyouts led by future managers. As a key shareholder, we provide the capital needed to fund the next growth cycle

Reprise d'entreprise
Target

Profitable B2B companies (excluding services) with an enterprise value between €1M and €5M

Investment range

€500k – €2.5M

Team

Gilles Alberici
Chairman
Julien Alberici
CEO
Jérémy Bastid
R&D Director
Thuy-Linh Mermier
Thuy Linh Mermier
Head of Administration, Finance & Legal
Lorédane Sauzaret
Executive Assistant

portfolio

Seed Financing

Sirius Neosight
Development of a universal marker for circulating tumour cells, enabling detection, monitoring, and therapeutic guidance in oncology.
Sirius Neosight
Development of a universal marker for circulating tumour cells, enabling detection, monitoring, and therapeutic guidance in oncology.

Company Creation

Acquisition

Alizé Pharma
Development of a stabilised analogue of unacylated ghrelin for the treatment of Prader-Willi syndrome and type 2 diabetes.
Alizé Pharma
Development of a stabilised analogue of unacylated ghrelin for the treatment of Prader-Willi syndrome and type 2 diabetes.
Alizé Pharma 2
Development of a PEGylated recombinant L-asparaginase for the treatment of rare onco-haematological diseases.
Alizé Pharma 2
Development of a PEGylated recombinant L-asparaginase for the treatment of rare onco-haematological diseases.
Amolyt Pharma
Development of therapeutic peptides targeting rare endocrine diseases.
Amolyt Pharma
Development of therapeutic peptides targeting rare endocrine diseases.
Glycode
Genetic engineering of yeast for the production of therapeutic proteins.
Glycode
Genetic engineering of yeast for the production of therapeutic proteins.
Graftys
Development, production, and commercialisation of synthetic calcium phosphate bone substitutes.
Graftys
Development, production, and commercialisation of synthetic calcium phosphate bone substitutes.
Ipsogen
Development and commercialisation of molecular diagnostic tests.
Ipsogen
Development and commercialisation of molecular diagnostic tests.
Juvise
Acquisition and commercialisation of princeps medicines.
Juvise
Acquisition and commercialisation of princeps medicines.
Antagene
Development of DNA tests and genetic analyses for dogs, cats, and horses, as well as genetic analysis for biodiversity management.
Antagene
Development of DNA tests and genetic analyses for dogs, cats, and horses, as well as genetic analysis for biodiversity management.
E(ye) Brain
Development and commercialisation of eye-tracking technology for the early diagnosis of neurological diseases.
E(ye) Brain
Development and commercialisation of eye-tracking technology for the early diagnosis of neurological diseases.
Night Swapping
A home exchange platform for holiday accommodation.
Night Swapping
A home exchange platform for holiday accommodation.
Mathym
Development and commercialisation of innovative nanomaterials for optical and biomedical applications.
Mathym
Development and commercialisation of innovative nanomaterials for optical and biomedical applications.
Docea Power
Modelling, simulation, and optimisation of energy consumption in SoCs (System on Chip) and associated platforms.
Docea Power
Modelling, simulation, and optimisation of energy consumption in SoCs (System on Chip) and associated platforms.

Dominique & Tom Alberici Foundation

Since 2008, our commitment: over 200 projects directly benefiting people with disabilities or cancer patients. Visit our website